PreciseDx Showcases New Clinical Data on AI Breast Cancer Test at SABCS

PreciseDx has shared an update. The company announced that three scientific presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS) will feature new data on PreciseBreast®, its AI-powered digital pathology test designed to assess breast cancer risk of recurrence. The accepted abstracts include: (1) a study on an AI digital pathology-based prognostic test using biopsy specimens to predict recurrence, (2) an AI-enabled phenotyping approach for triple-negative breast cancer, and (3) a real-world evaluation of PreciseBreast® for early-stage invasive breast cancer risk stratification in collaboration with Lankenau Medical Center/Main Line Health.

For investors, inclusion in SABCS—one of the leading global forums for breast cancer research—signals growing clinical validation and interest from the oncology community in PreciseDx’s technology. Positive data from these studies could strengthen the clinical credibility and utility of PreciseBreast®, supporting its adoption by healthcare providers and payers. This, in turn, may enhance the company’s competitive position in the emerging AI-enabled diagnostics and digital pathology market, potentially expanding its addressable market and underpinning future revenue growth. The real-world evaluation component is particularly relevant for reimbursement discussions and commercial scalability, as payers and providers increasingly require evidence of real-world effectiveness in addition to controlled clinical data.